Forbion — 2026 Investments
2 investments dated 2026 · listed companies and verified rows first · show all
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)
BoardZach Scheiner(Director)inMegan Krench(Director)
Board seatDmitrij Hristodorov· per SEC Form D
Co-investorsSanofi VenturesAvego BioScience CapitalRA CapitalSamsara BioCapital
Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
AI & Machine LearningBiotech
Pierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)Marie De Vulder(Chief Legal Officer Co-founder)Guy Peeters(Chief Financial Officer Co-founder)John-Paul Gallivan(Head of Development Co-founder)Fabrice Kolb(Head of Immunology Co-founder)Pieter Peeters(Operating & Technology Officer Co-founder)
Co-investorsLongwood FundSofinnova VenturesBAM ElevateFinchley Healthcare VenturesLuma GroupNovo Holdings+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.